NEO-811: A Novel Molecular Glue Degrader Targeting the ARNT/HIF Pathway in Kidney Cancer

NEO-811 is a first-in-class molecular glue degrader developed to target ARNT (HIF-1β), a critical component of the hypoxia-inducible factor signaling pathway in clear cell renal cell carcinoma (ccRCC). By promoting selective ARNT degradation through cereblon-mediated ubiquitination, NEO-811 aims to suppress tumor-promoting HIF activity more effectively than conventional inhibitors. This innovative targeted protein degradation strategy may overcome resistance associated with existing kidney cancer therapies. As NEO-811 advances through clinical development, it highlights the growing potential of molecular glue therapeutics to reshape precision oncology and expand treatment options for previously undruggable cancer targets.

Introduction: What Is NEO-811?

NEO-811 is an investigational molecular glue degrader designed to target difficult-to-drug cancer pathways through targeted protein degradation technology. Developed by Neomorph, the compound has attracted growing attention in oncology research because of its unique ability to degrade ARNT (aryl hydrocarbon receptor nuclear translocator), also known as HIF-1β. ARNT is a critical partner in the hypoxia-inducible factor (HIF) signaling pathway, which plays a major role in the development and progression of clear cell renal cell carcinoma (ccRCC), the most common subtype of kidney cancer.

In many ccRCC tumors, mutations in the von Hippel–Lindau (VHL) gene lead to abnormal activation of HIF signaling. This dysregulated pathway promotes tumor survival, angiogenesis, metabolic adaptation, and resistance to therapy. While several therapies have been developed to inhibit downstream components of the HIF pathway, NEO-811 introduces a different strategy by selectively eliminating ARNT itself through the ubiquitin–proteasome system.

Unlike conventional inhibitors that temporarily block protein activity, molecular glue degraders trigger the destruction of disease-driving proteins. NEO-811 works by recruiting cereblon, an E3 ubiquitin ligase receptor, to induce selective ARNT degradation. This innovative mechanism highlights the expanding potential of molecular glue therapeutics to address previously “undruggable” targets and may open new possibilities for precision oncology treatments in kidney cancer and beyond.

The Science Behind NEO-811: ARNT/HIF Pathway Explained

NEO-811 was developed to disrupt one of the most important signaling pathways involved in clear cell renal cell carcinoma (ccRCC): the hypoxia-inducible factor (HIF) pathway. In healthy cells, the von Hippel–Lindau (VHL) protein regulates oxygen sensing by promoting the degradation of HIF proteins under normal oxygen conditions. However, in most ccRCC cases, mutations or loss of the VHL gene prevent this regulation, leading to continuous activation of HIF signaling even when oxygen is sufficient.

The HIF pathway depends on the interaction between HIF-α subunits and ARNT, also known as HIF-1β. ARNT functions as a transcriptional partner that allows HIF complexes to activate genes involved in angiogenesis, cell proliferation, glucose metabolism, and tumor survival. Because ARNT is essential for HIF-driven transcription, it represents an attractive therapeutic target in kidney cancer biology.

NEO-811 uses a molecular glue mechanism to induce selective degradation of ARNT. Rather than inhibiting the protein directly, the compound recruits cereblon, an E3 ubiquitin ligase receptor, to promote ARNT ubiquitination and subsequent destruction by the proteasome. This strategy differs from conventional inhibitors by removing the target protein entirely from the cell.

By degrading ARNT and shutting down aberrant HIF signaling, NEO-811 may provide a novel approach for treating HIF-dependent tumors and overcoming limitations associated with existing targeted therapies.

Why NEO-811 Could Be a Breakthrough in ccRCC Treatment

Clear cell renal cell carcinoma (ccRCC) remains one of the most challenging kidney cancers to treat because of its strong dependence on abnormal hypoxia-inducible factor (HIF) signaling. Current therapies, including VEGF inhibitors, immune checkpoint inhibitors, and HIF-2α inhibitors such as belzutifan, have improved patient outcomes, but many individuals eventually develop resistance or experience limited long-term responses. This has created a strong demand for next-generation therapies that target the disease through new biological mechanisms.

NEO-811 may represent a major breakthrough because it targets ARNT (HIF-1β), a central component required for HIF-mediated transcription. Instead of blocking a single downstream pathway, NEO-811 aims to shut down HIF signaling more comprehensively by degrading ARNT itself. This broader suppression of tumor-promoting signals could potentially overcome some resistance mechanisms associated with existing targeted therapies.

Another important advantage of NEO-811 is its molecular glue degrader design. Unlike traditional inhibitors that require continuous target occupancy, molecular glues eliminate disease-driving proteins through the cell’s natural degradation machinery. This approach may provide stronger and longer-lasting biological effects while expanding access to previously “undruggable” targets.

Because VHL loss and HIF pathway activation are defining features of ccRCC, NEO-811 has the potential to become a first-in-class precision oncology therapy capable of reshaping future kidney cancer treatment strategies.

Clinical Development and Industry Interest in NEO-811

NEO-811 has rapidly gained attention in the biotechnology and oncology communities as one of the most advanced molecular glue degraders entering clinical development for clear cell renal cell carcinoma (ccRCC). The investigational therapy is currently being evaluated in the first-in-human Phase 1/2 clinical trial known as NEO-811-101, which focuses on patients with locally advanced or metastatic non-resectable ccRCC. The study is designed to assess safety, tolerability, pharmacokinetics, dose escalation, and preliminary antitumor activity of the compound.

The launch of this clinical trial represents a major milestone for Neomorph, the biotechnology company behind NEO-811. Founded in 2020, Neomorph specializes in molecular glue degraders and targeted protein degradation technologies aimed at previously “undruggable” disease targets. Industry interest in the company has grown significantly because molecular glue therapeutics are increasingly viewed as a next-generation strategy in precision medicine.

Preclinical studies presented at AACR 2026 demonstrated that NEO-811 induced selective and cereblon-dependent degradation of ARNT while suppressing HIF-related transcriptional programs in ccRCC models. Importantly, the compound also showed activity in models resistant to HIF-2α inhibitors, highlighting its potential therapeutic advantage.

As investment in targeted protein degradation continues to expand, NEO-811 is becoming an important example of how molecular glue technologies may transform future cancer drug discovery and treatment strategies.

Future Perspectives: What NEO-811 Means for Precision Oncology

NEO-811 represents more than a promising investigational therapy for clear cell renal cell carcinoma (ccRCC); it also highlights the growing impact of targeted protein degradation in precision oncology. By using a molecular glue mechanism to selectively degrade ARNT, NEO-811 demonstrates how researchers can now address proteins that were once considered “undruggable.” This shift could significantly expand the range of therapeutic targets available for cancer treatment.

The success of NEO-811 may also accelerate the development of additional molecular glue degraders for other HIF-driven malignancies and solid tumors. Because abnormal transcription factor signaling is involved in many cancers, targeted degradation technologies could provide a powerful alternative to conventional inhibitors. In the future, NEO-811 may also be explored in combination with immunotherapies, VEGF inhibitors, or HIF-2α inhibitors to improve treatment responses and delay resistance.

Despite its potential, several challenges remain. Researchers still need to better understand long-term safety, optimal patient selection, resistance mechanisms, and biomarker strategies. Clinical trial outcomes will ultimately determine whether ARNT degradation can deliver meaningful benefits for patients with advanced kidney cancer.